Targeted therapy / extracellular chemotherapeutic agents/antineoplastic agents L01
myeloid: CD33 (Gemtuzumab)
EML4-ALK (Crizotinib)
RET inhibitors: Vandetanib (Also VEGFR and EGFR). c-MET inhibitor: Cabozantinib (Also VEGFR2).